US20010008898A1 - Ether and amide compounds and preparation of thereof as antidiadetics. - Google Patents
Ether and amide compounds and preparation of thereof as antidiadetics. Download PDFInfo
- Publication number
- US20010008898A1 US20010008898A1 US09/756,701 US75670101A US2001008898A1 US 20010008898 A1 US20010008898 A1 US 20010008898A1 US 75670101 A US75670101 A US 75670101A US 2001008898 A1 US2001008898 A1 US 2001008898A1
- Authority
- US
- United States
- Prior art keywords
- compound
- general formula
- mentioned meanings
- reacted
- aromatic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 0 C*CC.CC.CC.CC1=CC(C)=C(C)C=C1.CC1=CC(F)=C(C)C(F)=C1.CC1=CC(F)=C(C)C(F)=C1.CC1=CC2=C(C=C1)OC(C#C(=O)=O)(C#C(=O)=O)O2.CC1=CC=C(C)C(C)=C1.CCC1=C(C)OC(C2=CC=C(C)C=C2)=N1.CCC1=CN=C(CC)C=C1.CCN(C)C1=NC=CC=C1.CNC(C)=O.COC Chemical compound C*CC.CC.CC.CC1=CC(C)=C(C)C=C1.CC1=CC(F)=C(C)C(F)=C1.CC1=CC(F)=C(C)C(F)=C1.CC1=CC2=C(C=C1)OC(C#C(=O)=O)(C#C(=O)=O)O2.CC1=CC=C(C)C(C)=C1.CCC1=C(C)OC(C2=CC=C(C)C=C2)=N1.CCC1=CN=C(CC)C=C1.CCN(C)C1=NC=CC=C1.CNC(C)=O.COC 0.000 description 17
- GWHJZXXIDMPWGX-UHFFFAOYSA-N CC1=CC=C(C)C(C)=C1 Chemical compound CC1=CC=C(C)C(C)=C1 GWHJZXXIDMPWGX-UHFFFAOYSA-N 0.000 description 14
- OHLUUHNLEMFGTQ-UHFFFAOYSA-N CNC(C)=O Chemical compound CNC(C)=O OHLUUHNLEMFGTQ-UHFFFAOYSA-N 0.000 description 4
- BHAAPTBBJKJZER-UHFFFAOYSA-N COC1=CC=C(N)C=C1 Chemical compound COC1=CC=C(N)C=C1 BHAAPTBBJKJZER-UHFFFAOYSA-N 0.000 description 4
- BNUHAJGCKIQFGE-UHFFFAOYSA-N COC1=CC=C([N+](=O)[O-])C=C1 Chemical compound COC1=CC=C([N+](=O)[O-])C=C1 BNUHAJGCKIQFGE-UHFFFAOYSA-N 0.000 description 4
- FLNSOAOUHFIBKF-UHFFFAOYSA-N CC.CC.CCC1=C(C)OC(C2=CC=C(C)C=C2)=N1 Chemical compound CC.CC.CCC1=C(C)OC(C2=CC=C(C)C=C2)=N1 FLNSOAOUHFIBKF-UHFFFAOYSA-N 0.000 description 3
- NLVQOBVZSUIZRO-UHFFFAOYSA-N CNC(=O)COOC Chemical compound CNC(=O)COOC NLVQOBVZSUIZRO-UHFFFAOYSA-N 0.000 description 3
- LECOJAIYOFYDJN-UHFFFAOYSA-N CNS(=O)(=O)C1=CC=C(C)C=C1.CNS(=O)(=O)C1=CC=C(COO)C=C1.CNS(=O)(=O)C1=CC=CS1 Chemical compound CNS(=O)(=O)C1=CC=C(C)C=C1.CNS(=O)(=O)C1=CC=C(COO)C=C1.CNS(=O)(=O)C1=CC=CS1 LECOJAIYOFYDJN-UHFFFAOYSA-N 0.000 description 3
- HBXFIXSFKULBOG-UHFFFAOYSA-N CC1=CC(F)=C(C)C(F)=C1 Chemical compound CC1=CC(F)=C(C)C(F)=C1 HBXFIXSFKULBOG-UHFFFAOYSA-N 0.000 description 2
- MSHFRERJPWKJFX-UHFFFAOYSA-N COC1=CC=C(CO)C=C1 Chemical compound COC1=CC=C(CO)C=C1 MSHFRERJPWKJFX-UHFFFAOYSA-N 0.000 description 2
- ROQYNKQIBDPEFS-UHFFFAOYSA-N C.CC.CC.CC.CC.CC.CC.CC(=O)CC1=C(C)OC(C2=CC=C(C)C=C2)=N1.CC1=CC=C(C2=NC(CC(=O)O)=C(C)O2)C=C1.CC1=CC=C(NC(=O)CC2=C(C)NC(C3=CC=C(C)C=C3)=N2)C=C1.NC1=CC=C([N+](=O)[O-])C=C1 Chemical compound C.CC.CC.CC.CC.CC.CC.CC(=O)CC1=C(C)OC(C2=CC=C(C)C=C2)=N1.CC1=CC=C(C2=NC(CC(=O)O)=C(C)O2)C=C1.CC1=CC=C(NC(=O)CC2=C(C)NC(C3=CC=C(C)C=C3)=N2)C=C1.NC1=CC=C([N+](=O)[O-])C=C1 ROQYNKQIBDPEFS-UHFFFAOYSA-N 0.000 description 1
- MNGDSXKHWIKBHK-UHFFFAOYSA-N C.CCC1=CN=C(CC)C=C1 Chemical compound C.CCC1=CN=C(CC)C=C1 MNGDSXKHWIKBHK-UHFFFAOYSA-N 0.000 description 1
- ZYLVBABKTAOXEK-UHFFFAOYSA-N C.CCN(C)C1=CC=CC=N1 Chemical compound C.CCN(C)C1=CC=CC=N1 ZYLVBABKTAOXEK-UHFFFAOYSA-N 0.000 description 1
- AQYDOPHYIJZZCD-UHFFFAOYSA-N C.O=S(=O)(Cl)C1=CC=CC=C1.O=S(=O)(Cl)C1=CC=CS1 Chemical compound C.O=S(=O)(Cl)C1=CC=CC=C1.O=S(=O)(Cl)C1=CC=CS1 AQYDOPHYIJZZCD-UHFFFAOYSA-N 0.000 description 1
- HCKMMQRBNMNRQQ-UHFFFAOYSA-N C=C(OO)S([O])(=O)=O.CC.CC.CC.CC.CC.CC.CC1=CC=C(C2=NC(CCOC3=CC=C(N)C=C3)=C(C)O2)C=C1.CC1=CC=C(C2=NC(CCOC3=CC=C(N)C=C3)=C(C)O2)C=C1.CNC1=CC=C(OCCC2=C(C)OC(C3=CC=C(C)C=C3)=N2)C=C1 Chemical compound C=C(OO)S([O])(=O)=O.CC.CC.CC.CC.CC.CC.CC1=CC=C(C2=NC(CCOC3=CC=C(N)C=C3)=C(C)O2)C=C1.CC1=CC=C(C2=NC(CCOC3=CC=C(N)C=C3)=C(C)O2)C=C1.CNC1=CC=C(OCCC2=C(C)OC(C3=CC=C(C)C=C3)=N2)C=C1 HCKMMQRBNMNRQQ-UHFFFAOYSA-N 0.000 description 1
- SOTRHAVZASQEDV-UHFFFAOYSA-N C=O.CC1=C(CCOC2=CC=C(C=O)C=C2)N=C(C2=CC=CC=C2)O1.CC1=C(CCOC2=CC=C(CNS(=O)(=O)C(F)(F)F)C=C2)N=C(C2=CC=CC=C2)O1.CC1=C(CCOC2=CC=C(NS(=O)(=O)C(F)(F)F)C=C2)N=C(C2=CC=CC=C2)O1.CC1=C(CCOC2=CC=C(NS(=O)CO)C=C2)N=C(C2=CC=CC=C2)O1.CC1=C(CCOC2=CC=C(S(N)(=O)(O)C3=CC=C(O)C=C3)C=C2)N=C(C2=CC=CC=C2)O1.CC1=C(CCOC2=CC=C(S(N)(=O)(O)C3=CC=CC=C3)C=C2)N=C(C2=CC=CC=C2)O1.CC1=C(CCOC2=CC=C(S(N)(=O)(O)C3=CC=CS3)C=C2)N=C(C2=CC=CC=C2)O1.CC1=C(CCOC2=CC=C(S(N)(=O)(O)CCOO)C=C2)N=C(C2=CC=CC=C2)O1.CC1=CC=C(S(N)(=O)(O)C2=CC=C(OCCC3=C(C)OC(C4=CC=CC=C4)=N3)C=C2)C=C1.CCC1=CN=C(CCOC2=CC=C(C(F)(F)F)C=C2)C=C1.N=S(=O)=O Chemical compound C=O.CC1=C(CCOC2=CC=C(C=O)C=C2)N=C(C2=CC=CC=C2)O1.CC1=C(CCOC2=CC=C(CNS(=O)(=O)C(F)(F)F)C=C2)N=C(C2=CC=CC=C2)O1.CC1=C(CCOC2=CC=C(NS(=O)(=O)C(F)(F)F)C=C2)N=C(C2=CC=CC=C2)O1.CC1=C(CCOC2=CC=C(NS(=O)CO)C=C2)N=C(C2=CC=CC=C2)O1.CC1=C(CCOC2=CC=C(S(N)(=O)(O)C3=CC=C(O)C=C3)C=C2)N=C(C2=CC=CC=C2)O1.CC1=C(CCOC2=CC=C(S(N)(=O)(O)C3=CC=CC=C3)C=C2)N=C(C2=CC=CC=C2)O1.CC1=C(CCOC2=CC=C(S(N)(=O)(O)C3=CC=CS3)C=C2)N=C(C2=CC=CC=C2)O1.CC1=C(CCOC2=CC=C(S(N)(=O)(O)CCOO)C=C2)N=C(C2=CC=CC=C2)O1.CC1=CC=C(S(N)(=O)(O)C2=CC=C(OCCC3=C(C)OC(C4=CC=CC=C4)=N3)C=C2)C=C1.CCC1=CN=C(CCOC2=CC=C(C(F)(F)F)C=C2)C=C1.N=S(=O)=O SOTRHAVZASQEDV-UHFFFAOYSA-N 0.000 description 1
- QZBBJBLWUZYRJA-UHFFFAOYSA-N CC.CC.CC.CC.CC.CC.CC.CC.CC.CC.CC1=CC=C(C)C(C)=C1.CC1=CC=C(C2=NC(CCOC3=CC=C(N)C=C3)=C(C)O2)C=C1.CC1=CC=C(C2=NC(CCOC3=CC=C(NC(=O)COO)C=C3)=C(C)O2)C=C1.CN.COOCC(=O)N(C)C1=CC=C(OCCC2=C(C)OC(C3=CC=C(C)C=C3)=N2)C=C1.COOCC(=O)NC1=CC=C(OCCC2=C(C)OC(C3=CC=C(C)C=C3)=N2)C=C1.COOCC(=O)NC1=CC=C(OCCC2=C(C)OC(C3=CC=C(C)C=C3)=N2)C=C1 Chemical compound CC.CC.CC.CC.CC.CC.CC.CC.CC.CC.CC1=CC=C(C)C(C)=C1.CC1=CC=C(C2=NC(CCOC3=CC=C(N)C=C3)=C(C)O2)C=C1.CC1=CC=C(C2=NC(CCOC3=CC=C(NC(=O)COO)C=C3)=C(C)O2)C=C1.CN.COOCC(=O)N(C)C1=CC=C(OCCC2=C(C)OC(C3=CC=C(C)C=C3)=N2)C=C1.COOCC(=O)NC1=CC=C(OCCC2=C(C)OC(C3=CC=C(C)C=C3)=N2)C=C1.COOCC(=O)NC1=CC=C(OCCC2=C(C)OC(C3=CC=C(C)C=C3)=N2)C=C1 QZBBJBLWUZYRJA-UHFFFAOYSA-N 0.000 description 1
- VKECSJMDKSYUMG-UHFFFAOYSA-N CC.CC.CC.CC.CC.CC.CC1=CC=C(C2=NC(CCOC3=CC=C(C)C(C)=C3)=C(C)O2)C=C1.CC1=CC=C(C2=NC(CCOC3=CC=C(COO)C(C)=C3)=C(C)O2)C=C1.CC1=CC=C(C2=NC(CCOC3=CC=C(COO)C(O)=C3)=C(C)O2)C=C1 Chemical compound CC.CC.CC.CC.CC.CC.CC1=CC=C(C2=NC(CCOC3=CC=C(C)C(C)=C3)=C(C)O2)C=C1.CC1=CC=C(C2=NC(CCOC3=CC=C(COO)C(C)=C3)=C(C)O2)C=C1.CC1=CC=C(C2=NC(CCOC3=CC=C(COO)C(O)=C3)=C(C)O2)C=C1 VKECSJMDKSYUMG-UHFFFAOYSA-N 0.000 description 1
- QAYVAFYDHUJLBD-UHFFFAOYSA-N CC.CC.CC1=CC(C)=C(C)C=C1.CC1=CC(F)=C(C)C(F)=C1.CC1=CC(F)=C(C)C(F)=C1.CC1=CC2=C(C=C1)OC(C#C(=O)=O)(C#C(=O)=O)O2.CC1=CC=C(C)C(C)=C1.CCC1=C(C)OC(C2=CC=C(C)C=C2)=N1.CCC1=CN=C(CC)C=C1.CCN(C)C1=NC=CC=C1.CNC(C)=O.COC Chemical compound CC.CC.CC1=CC(C)=C(C)C=C1.CC1=CC(F)=C(C)C(F)=C1.CC1=CC(F)=C(C)C(F)=C1.CC1=CC2=C(C=C1)OC(C#C(=O)=O)(C#C(=O)=O)O2.CC1=CC=C(C)C(C)=C1.CCC1=C(C)OC(C2=CC=C(C)C=C2)=N1.CCC1=CN=C(CC)C=C1.CCN(C)C1=NC=CC=C1.CNC(C)=O.COC QAYVAFYDHUJLBD-UHFFFAOYSA-N 0.000 description 1
- VGKBZZXCDYWITP-UHFFFAOYSA-N CC.CC.CC1=CC=C(C(=O)Cl)C(C)=C1.CC1=CC=C(CCOO)C(C)=C1.CC1=CC=C(COO)C(C)=C1.COOCCC1=CC=C(C)C=C1C.COOCCC1=CC=C(O)C=C1C.COOCCC1=CC=C(OCCC2=C(C)OC(C3=CC=C(C)C=C3)=N2)C=C1C Chemical compound CC.CC.CC1=CC=C(C(=O)Cl)C(C)=C1.CC1=CC=C(CCOO)C(C)=C1.CC1=CC=C(COO)C(C)=C1.COOCCC1=CC=C(C)C=C1C.COOCCC1=CC=C(O)C=C1C.COOCCC1=CC=C(OCCC2=C(C)OC(C3=CC=C(C)C=C3)=N2)C=C1C VGKBZZXCDYWITP-UHFFFAOYSA-N 0.000 description 1
- DZEVKNXVDPVAIW-UHFFFAOYSA-N CC.CC.CC1=CC=C(C2=NC(CCOC3=CC=C(CS(N)(=O)=O)C(O)=C3)=C(C)O2)C=C1.CC1=CC=C(CO)C(C)=C1.CC1=CC=C(CO)C(C)=C1.CC1=CC=C(CS(=O)(=O)O)C(C)=C1.CC1=CC=C(CS(N)(=O)=O)C(C)=C1.NS(=O)(=O)CC1=CC=C(O)C=C1O Chemical compound CC.CC.CC1=CC=C(C2=NC(CCOC3=CC=C(CS(N)(=O)=O)C(O)=C3)=C(C)O2)C=C1.CC1=CC=C(CO)C(C)=C1.CC1=CC=C(CO)C(C)=C1.CC1=CC=C(CS(=O)(=O)O)C(C)=C1.CC1=CC=C(CS(N)(=O)=O)C(C)=C1.NS(=O)(=O)CC1=CC=C(O)C=C1O DZEVKNXVDPVAIW-UHFFFAOYSA-N 0.000 description 1
- YULVVQOKWGQCEU-UHFFFAOYSA-M CC1=C(O)C=C(O)C=C1.COC1=CC(OC)=C(S(=O)(=O)Cl)C=C1.COC1=CC(OC)=C(S(=O)(=O)O[K])C=C1.COC1=CC=CC(OC)=C1.NS(=O)(=O)C1=C(O)C=C(O)C=C1.O=P(Cl)(Cl)Cl Chemical compound CC1=C(O)C=C(O)C=C1.COC1=CC(OC)=C(S(=O)(=O)Cl)C=C1.COC1=CC(OC)=C(S(=O)(=O)O[K])C=C1.COC1=CC=CC(OC)=C1.NS(=O)(=O)C1=C(O)C=C(O)C=C1.O=P(Cl)(Cl)Cl YULVVQOKWGQCEU-UHFFFAOYSA-M 0.000 description 1
- YXNGRHAEAFXAPB-UHFFFAOYSA-N CC1=CC(F)=C(COO)C(F)=C1 Chemical compound CC1=CC(F)=C(COO)C(F)=C1 YXNGRHAEAFXAPB-UHFFFAOYSA-N 0.000 description 1
- XBUOBOGBXVDWOQ-UHFFFAOYSA-N CC1=CC2=C(C=C1)OC(COO)(COO)O2 Chemical compound CC1=CC2=C(C=C1)OC(COO)(COO)O2 XBUOBOGBXVDWOQ-UHFFFAOYSA-N 0.000 description 1
- FXPVUQYUXHAMAX-UHFFFAOYSA-N CC1=CC=C(C(=O)COO)C=C1 Chemical compound CC1=CC=C(C(=O)COO)C=C1 FXPVUQYUXHAMAX-UHFFFAOYSA-N 0.000 description 1
- ZBSULTAEXKVNCO-UHFFFAOYSA-N CC1=CC=C(C(=O)NS(=O)(=O)C2=CC=CS2)C=C1.CC1=CC=C(C(=O)NS(C)(=O)=O)C=C1 Chemical compound CC1=CC=C(C(=O)NS(=O)(=O)C2=CC=CS2)C=C1.CC1=CC=C(C(=O)NS(C)(=O)=O)C=C1 ZBSULTAEXKVNCO-UHFFFAOYSA-N 0.000 description 1
- URLKBWYHVLBVBO-UHFFFAOYSA-N CC1=CC=C(C)C=C1 Chemical compound CC1=CC=C(C)C=C1 URLKBWYHVLBVBO-UHFFFAOYSA-N 0.000 description 1
- FANKJYHSXCHVPW-UHFFFAOYSA-N CC1=CC=C(CNS(=O)(=O)C(F)(F)F)C=C1.CC1=CC=C(CNS(C)(=O)=O)C=C1 Chemical compound CC1=CC=C(CNS(=O)(=O)C(F)(F)F)C=C1.CC1=CC=C(CNS(C)(=O)=O)C=C1 FANKJYHSXCHVPW-UHFFFAOYSA-N 0.000 description 1
- LTHDZTVTKDBCGH-UHFFFAOYSA-N CC1=CC=C(COO)C(O)=C1 Chemical compound CC1=CC=C(COO)C(O)=C1 LTHDZTVTKDBCGH-UHFFFAOYSA-N 0.000 description 1
- MIYYDGBVDYDNLP-UHFFFAOYSA-N CC1=CC=C(NS(=O)(=O)C2=CC=C(COO)C=C2)C=C1 Chemical compound CC1=CC=C(NS(=O)(=O)C2=CC=C(COO)C=C2)C=C1 MIYYDGBVDYDNLP-UHFFFAOYSA-N 0.000 description 1
- BEROMCHRMVTTDJ-UHFFFAOYSA-N CC1=CC=C(NS(=O)(=O)C2=CC=CC=C2)C=C1.CC1=CC=C(NS(=O)(=O)C2=CC=CS2)C=C1 Chemical compound CC1=CC=C(NS(=O)(=O)C2=CC=CC=C2)C=C1.CC1=CC=C(NS(=O)(=O)C2=CC=CS2)C=C1 BEROMCHRMVTTDJ-UHFFFAOYSA-N 0.000 description 1
- IUGAOJPITHMAJS-UHFFFAOYSA-N CC1=CC=C(NS(=O)(=O)CCOO)C=C1 Chemical compound CC1=CC=C(NS(=O)(=O)CCOO)C=C1 IUGAOJPITHMAJS-UHFFFAOYSA-N 0.000 description 1
- IWDCLRJOBJJRNH-UHFFFAOYSA-N CC1=CC=C(O)C=C1 Chemical compound CC1=CC=C(O)C=C1 IWDCLRJOBJJRNH-UHFFFAOYSA-N 0.000 description 1
- OIALIKXMLIAOSN-UHFFFAOYSA-N CCCC1=NC=CC=C1 Chemical compound CCCC1=NC=CC=C1 OIALIKXMLIAOSN-UHFFFAOYSA-N 0.000 description 1
- MKTSSBCZDAXGGO-UHFFFAOYSA-N CCN(C)C1=NC=CC=C1 Chemical compound CCN(C)C1=NC=CC=C1 MKTSSBCZDAXGGO-UHFFFAOYSA-N 0.000 description 1
- JCUSJGYOSCIGCV-UHFFFAOYSA-N CCS(=O)(=O)NC1=CC=C(OC)C=C1 Chemical compound CCS(=O)(=O)NC1=CC=C(OC)C=C1 JCUSJGYOSCIGCV-UHFFFAOYSA-N 0.000 description 1
- LWWBBDFBZJCKHQ-UHFFFAOYSA-N CN=CC1=CC=C(OC)C=C1 Chemical compound CN=CC1=CC=C(OC)C=C1 LWWBBDFBZJCKHQ-UHFFFAOYSA-N 0.000 description 1
- BUMTZRCSKADHJI-UHFFFAOYSA-N CNC1=CC(F)=C(C)C(F)=C1.CNC1=CC(F)=C(C)C(F)=C1 Chemical compound CNC1=CC(F)=C(C)C(F)=C1.CNC1=CC(F)=C(C)C(F)=C1 BUMTZRCSKADHJI-UHFFFAOYSA-N 0.000 description 1
- FKOZWXLWJBAFPL-UHFFFAOYSA-N CNC1=CC=C(C)C=C1C.CNC1=CC=C(C)C=C1C Chemical compound CNC1=CC=C(C)C=C1C.CNC1=CC=C(C)C=C1C FKOZWXLWJBAFPL-UHFFFAOYSA-N 0.000 description 1
- POVSDXPEJZMSEJ-UHFFFAOYSA-N COC1=C(F)C=C(N)C=C1F Chemical compound COC1=C(F)C=C(N)C=C1F POVSDXPEJZMSEJ-UHFFFAOYSA-N 0.000 description 1
- HHWLNWSVKHLZDB-UHFFFAOYSA-N COC1=C(F)C=C([N+](=O)[O-])C=C1F Chemical compound COC1=C(F)C=C([N+](=O)[O-])C=C1F HHWLNWSVKHLZDB-UHFFFAOYSA-N 0.000 description 1
- IDPURXSQCKYKIJ-UHFFFAOYSA-N COC1=CC=C(CN)C=C1 Chemical compound COC1=CC=C(CN)C=C1 IDPURXSQCKYKIJ-UHFFFAOYSA-N 0.000 description 1
- WZUBICZIDUTTNJ-UHFFFAOYSA-N COC1=CC=C(CNCC2=CC=CC=C2)C=C1 Chemical compound COC1=CC=C(CNCC2=CC=CC=C2)C=C1 WZUBICZIDUTTNJ-UHFFFAOYSA-N 0.000 description 1
- NQKOZSGQMDFMHY-UHFFFAOYSA-N COC1=CC=C(COO)C=C1 Chemical compound COC1=CC=C(COO)C=C1 NQKOZSGQMDFMHY-UHFFFAOYSA-N 0.000 description 1
- CDGNLUSBENXDGG-UHFFFAOYSA-N COC1=CC=C(N)C(C)=C1 Chemical compound COC1=CC=C(N)C(C)=C1 CDGNLUSBENXDGG-UHFFFAOYSA-N 0.000 description 1
- RTZOGYCMIMOVHU-UHFFFAOYSA-N COC1=CC=C([N+](=O)[O-])C(C)=C1 Chemical compound COC1=CC=C([N+](=O)[O-])C(C)=C1 RTZOGYCMIMOVHU-UHFFFAOYSA-N 0.000 description 1
- VUMSHNPRBPHIIN-UHFFFAOYSA-N COOCC(=O)C1=CC=C(OC)C=C1 Chemical compound COOCC(=O)C1=CC=C(OC)C=C1 VUMSHNPRBPHIIN-UHFFFAOYSA-N 0.000 description 1
- YRCBYGRATGCELU-UHFFFAOYSA-N COOCC1=C(F)C=C(O)C=C1F Chemical compound COOCC1=C(F)C=C(O)C=C1F YRCBYGRATGCELU-UHFFFAOYSA-N 0.000 description 1
- HRMOGFBTJOOUSE-UHFFFAOYSA-N COOCC1=C(F)C=C(OC)C=C1F Chemical compound COOCC1=C(F)C=C(OC)C=C1F HRMOGFBTJOOUSE-UHFFFAOYSA-N 0.000 description 1
- OTIIJTCPBOEMCV-UHFFFAOYSA-N COOCC1=CC=C(O)C=C1O Chemical compound COOCC1=CC=C(O)C=C1O OTIIJTCPBOEMCV-UHFFFAOYSA-N 0.000 description 1
- KHSNSMQPJZUPDL-UHFFFAOYSA-N COOCC1=CC=C(OC)C=C1O Chemical compound COOCC1=CC=C(OC)C=C1O KHSNSMQPJZUPDL-UHFFFAOYSA-N 0.000 description 1
- QGMLMMRSQWLERM-UHFFFAOYSA-N COOCC1=CC=C(S(=O)(=O)Cl)C=C1 Chemical compound COOCC1=CC=C(S(=O)(=O)Cl)C=C1 QGMLMMRSQWLERM-UHFFFAOYSA-N 0.000 description 1
- NKCMIGZDDLGBSH-UHFFFAOYSA-N COOCC1=CC=C(S(=O)(=O)NC2=CC=C(OC)C=C2)C=C1 Chemical compound COOCC1=CC=C(S(=O)(=O)NC2=CC=C(OC)C=C2)C=C1 NKCMIGZDDLGBSH-UHFFFAOYSA-N 0.000 description 1
- JQPBFDQAZVTSMR-UHFFFAOYSA-N NC1=CC2=C(C=C1)OC(COO)(COO)O2 Chemical compound NC1=CC2=C(C=C1)OC(COO)(COO)O2 JQPBFDQAZVTSMR-UHFFFAOYSA-N 0.000 description 1
- WGQKYBSKWIADBV-UHFFFAOYSA-N NCC1=CC=CC=C1 Chemical compound NCC1=CC=CC=C1 WGQKYBSKWIADBV-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/28—Radicals substituted by singly-bound oxygen or sulphur atoms
- C07D213/30—Oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D263/32—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Definitions
- This invention is regarding to new ether and/or amide derivatives which are useful for the treatment of diabetes and a pharmaceutical composition containing these compounds as active ingredients.
- Biguanide and sulfonyl urea derivatives have been used as anti-diabetics so far. But these compounds have some drawbacks. For instance, biguanide compounds cause diabetic acidosis and sulfonyl urea compounds often cause hypoglycemia and it is required to be careful for taking these drugs.
- Troglitazone T. Yoshioka et al., J.Med.Chem. 1989,32,421
- Pioglitazone H. Ikeda et al., J.Med.Chem. 1992,35,2617
- Rosiglitazone B. C. C. Cantello et al., J.Med.Chem. 1994,37, 3977
- Thiazolidine-2,4-dione derivatives are mentioned as Thiazolidine-2,4-dione derivatives and Troglitazone is applied for clinical use.
- oxazoline-2,4-diones are reported such as oxazoline-2,4-dione (R. L. Dow et al., J.Med.Chem. 1991,34,1538), 1-oxo-2,4-diazoline-3,5-dione (S. W. Goldstein et al., J.Med.Chem. 1993,36,2238), ⁇ -amino carboxylic acid (R. A. DeFronzo, Diabetes, 1988,37,667), and Dicarboxylic acid ester (H. Shinkai et al., J.Med.Chem.1998,41,1927).
- the present invention concerns ether and amide compounds which enhance insulin action and show hypoglycemic activity with low toxicities and a pharmaceutical composition containing these compounds as active ingredients.
- the invention is the compounds as shown in general formula (I) and its pharmaceutically acceptable salts and a composition containing these compounds as active ingredients.
- n is 1 or 2.
- R 3 is OH—, CH 3 SO 2 NH—, CF 3 SO 2 NH—, CH 3 SO 2 NHCH 2 —, CF 3 SO 2 NHCH 2 —, HOOC—, CH 3 OOC—,
- R 8 NHSO 2 —, R 8 —NHSO 2 —CH 2 —, HOOC—CH 2 —O—, HSO 3 N ⁇ CH—, or R 9 —SO 2 NHCO—;
- R 4 is H, OH, O-alkyl or O—CH 2 OCH 3 ;
- R 5 is H, halogen atom, —CH 2 COOH or OH;
- R 6 and R 7 are hydrogen, t-butyl or pyrolidyl
- R 8 is hydrogen or lower alkyl
- R 9 is alkyl or thienyl
- R 10 is lower alkyl
- R 1 is
- R 3 is CH 3 SO 2 NH— or CF 3 SO 2 NH— and R 4 is H.
- the compounds can be obtained by means of the following reaction diagram: Asparatic acid ⁇ -methyl ester (2). (J.Arg.Chem.Soc.Japan, 1951-1952,25,129):C.A.47,6065i or R. L. Prestige et al., J.Org.Chem. 1975,40,3287 as a starting material is converted to compound (3) by the known method (B. Helvin et al., J.Med.Chem. 1992,35,1853) and compound (3) is tosylated or mesylated to obtain compound (4).
- R 1 is
- R 3 is HOOCCH 2 SO 2 NH— and R 4 is H.
- the above mentioned compound (9) is obtained by the chlorination of sulfoacetic acid (HOOCCH 2 SO 3 H(10)) with SOCl 2 and then reacted with alcohol (R. L. Hinman et al. (J.Am.Chem. Soc. 1959,81,5655), (H. T. Lee et al., Bioorg.Med.Chem.Lett. 1998,8,289).
- R 1 is
- R 3 is HOOC—CONH— and R 4 is H.
- R 3 is CH 3 SO 2 NHCH 2 —, CF 3 SO 2 NHCH 2 — and HOOC—CONH—, and R 4 is H.
- R 1 is
- R 3 is HOOC— or CH 3 OOC— and R 4 is —OH or —O-alkyl.
- compound (32) and compound (3) is subjected to the MITSUNOBU reaction to obtain the compound (33) which is the compound of general formula (I).
- compound (33) can be converted to compound (34) and compound (36) as shown in the following diagram.
- R 1 is
- R 3 is NH 2 SO 3 — or alkyl-NHSO 2 — and R 4 is —OH.
- R 3 is CH 3 SO 2 NH— or CF 3 SO 2 NH—.
- compound (53) is subjected to the MITSUNOBU reaction to obtain compound (54) and reduction of compound (54) yields compound (55).
- Compound (55) is converted to compound (56) according to the method of the preparation of compound (42) from compound (39).
- R 1 is
- R 3 is —COOH
- compound (57) is reacted with compound (4) and obtain the ether compound (58) and the resulting compound (58) is hydrolyzed to obtain compound (59) which is the compound of general formula (I).
- R 1 is
- R 3 is MeOOCCH 2 —
- R 4 is —O-alkyl
- R 1 is
- R 3 is NH 2 SO 2 CH 2 — or alkyl-NHSO 2 CH 2 — and R 4 is OH or —O-alkyl.
- R 1 is
- R 3 is CH 3 SO 2 NH— or CF 3 SO 2 NH—, and R 4 is H.
- glutamic acid ⁇ -methyl ester (16) is used in stead of aspartic acid ⁇ -methyl ester (2).
- Compound (17) is obtained from compound (16) by the same method as compound (3) is obtained from compound (2).
- R 3 is CH 3 SO 2 NH— or CF 3 SO 2 NH—, and R 4 is H.
- R 3 is CH 3 SO 2 NH— or CF 3 SO 2 NH—
- R 4 is —OH or —O-alkyl
- compound (37) is reacted with HO—R 2 to obtain compound (38) and compound (38) is hydrogenated to compound (39), or compound (38) is alkylated to compound (40) and reduction of compound (40) is resulting compound (41) .
- compound (39) or (41) are reacted with RSO 2 Cl and obtain compound (42) or compound (43).
- compound (42) and (43) can be obtained by using the reported method of coupling reaction of fluorobenzene and alcholol (Bioorg.Med.Chem.Lett., 1994,4 (10),1181). Namely, 2—OMOM (methoxy methyl)-4-fluoro nitrozenzene (45) is reacted with HO—R 2 to give compound (46) and resulting compound (46) is reduced to obtain compound (47).
- compound (49) is also converted to compound (41), and compound (43) is obtained from compound (41) by the same method as compound (48) is obtained from compound (46).
- R 3 is CH 3 SO 2 NH— or CF 3 SO 2 NH—
- R 4 is —H.
- compound (28) obtained from 2-chloropyridine (26) or 2-methyl amino pyridine (27), is tosylated or mesylated to obtain compound (29).
- Compound (29) is subjected to coupling reaction with nitro phenol and obtained compound (30) using the same manner to obtain compound (3).
- Resulting compound (30) is reduced to obtain compound (31) and compound (31) is reacted several sulfonyl chlorides (7), sulfonic acid anhydrides (8), EtOOC.CH 2 SO 2 Cl and methyloxalate to obtain the compound of general formula (I).
- A is —NH—CO—
- R 1 is
- R 3 is CH 3 SO 2 NH— or CF 3 SO 2 NH—
- R 4 is —H.
- compound (67) is obtained according to the reported method (J.Med.Chem. 1999,35,1853) and compound (67) is hydrolyzed to obtain compound (68). After chlorination of compound (68), obtained chloride is reacted with p-nitroaniline to obtain compound (69).
- compound (69) is hydrogenated to obtain compound (70) according to the same method to prepare compound (5).
- Compound (70) is reacted several sulfonyl chlorides (7), sulfonic acid anhydrides (8), EtOOC.CH 2 SO 2 Cl or methyloxalate to obtain the compound of general formula (I).
- carboxylic acid of compound (71) is reacted with CDI (Carbonyl Diimidazole) and then subjected to react with sulfamine of compound (72) in the presence of DBU (1,8-Diazabicyclo[5,4,0]undeca-7-ene) and obtain the compound of general formula (I).
- CDI Carbonyl Diimidazole
- DBU 1,8-Diazabicyclo[5,4,0]undeca-7-ene
- R 1 contains pyridine base
- salts of inorganic and organic acids are mentioned.
- hydrochloride and sulfate are mentioned.
- organic acid acetate, succinate and fumalate are mentioned.
- a compound of general formula (I) can be used itself or formulated to pharmaceutical product such as powder, granule, tablet and capsule by known pharmaceutical technology.
- Test compounds were suspended in 0.5% Methyl cellulose solution and administered (p.o.) to db/db mice (obtained from Nihon Clea) at a range of 3-30 mg/kg once a day for four consecutive days. Troglitazone (300 mg/kg) was also administered for control. The results is shown in Table 1.
- step (c) To a mixture of 0.4 g of the compound obtained from the above mentioned step (c) and 0.28 mL of triethylamine in dichloroethane (4 mL) and 0.16 mL of mesyl chloride were added and stirred at 30° C. for 30 minutes. The reaction mixture was poured into water and extracted with ethyl acetate. The ethyl acetate phase was washed with satd. NH 4 Cl solution, water and satd. NaCl solution and dried over anhydrous Na 2 SO 4 and filtrated.
- Example 10 step (a) The compound (1.85 g) obtained from the above mentioned Example 10 step (a) was hydrogenated as same manner as Example 1 step (c) and obtained the oily objective compound (1.62 g, 98.2%).
- Example 11 step (a) The compound (5.85 g) obtained from the above mentioned Example 11 step (a) was hydrogenated by the same procedure described in Example 1 step (c) and obtained the objective compound (2.12 g, 40.7%).
- step (a) The compound obtained from the above mentioned step (a) was reduced with hydrogen in a similar manner described in Example 1 step (c) and the resulting compound was reacted with trifluoromethanesulfonic acid anhydride in a similar manner described in Experimental 1 step (d). After removing of the protection group (MOM, methoxymethyl), the residue was recrystallized from the mixture of ethyl acetate and n-hexane to obtain the colorless objective compound (compound 33). mp-134-135° C.
- MOM protection group
- Example 39 step (a) 2-(N-Methyl, N-hydroxyethyl)-amino pyridine in Example 39 step (a) was reacted with 4-fluoro-2-methoxy-nitrobenzene and the resulting product was treated with in a similar manner described in Example 1 step (c) to obtain the oily objective compound 45.
- This invention concerns to novel ether and/or amide derivatives which enhance insulin action and show hypoglycemic activities with low toxicities and useful for antidiabetics.
Abstract
Ether and amide derivatives are disclosed, which are represented by the following formula (I) and its pharmaceutical acceptable salt, and which are useful for the treatment of diabetes.
R8—NHSO2—, R8—NHSO2—CH2—, HOOC—CH2—O—, HSO3N═CH—, or R9—SO2NHCO—;
R4 is H, OH, O-alkyl or O—CH2OCH3;
R5 is H, halogen atom, —CH2COOH or OH;
R6 and R7 are hydrogen, t-butyl or pyrolidyl;
R8 is hydrogen or lower alkyl;
R9 is alkyl or thienyl;
R10 is lower alkyl)
or a pharmaceutically acceptable salt.
Description
- Field of the Invention
- This invention is regarding to new ether and/or amide derivatives which are useful for the treatment of diabetes and a pharmaceutical composition containing these compounds as active ingredients.
- Current Technology
- Biguanide and sulfonyl urea derivatives have been used as anti-diabetics so far. But these compounds have some drawbacks. For instance, biguanide compounds cause diabetic acidosis and sulfonyl urea compounds often cause hypoglycemia and it is required to be careful for taking these drugs.
- Recently, thiazolidine-2,4-dion derivatives are reported to have blood glucose lowering activities.
- For example, Troglitazone (T. Yoshioka et al., J.Med.Chem. 1989,32,421), Pioglitazone (H. Ikeda et al., J.Med.Chem. 1992,35,2617) or Rosiglitazone (B. C. C. Cantello et al., J.Med.Chem. 1994,37, 3977) are mentioned as Thiazolidine-2,4-dione derivatives and Troglitazone is applied for clinical use.
- However, these thiazolidime-2,4-dione compound are reported to cause of liver toxicity (R. Perfetti et al., Diabetes/Metabolism Review 1998,14(3),207) and further, side effect to troglitazone treatment have been reported. They include cardiomegaly and hepatic malfunction such as increasements of amino transferase (AST), alanin transferees (ALT), and lactic dehydrogenase (LDH). (R. R. Henry, Endocrinol.Metab,Clin,North Am. 1997,26,553).
- To alleviate the side effect of thiazolidine-2,4-dione derivatives, several non-thiazolidine-2,4-diones are reported such as oxazoline-2,4-diones are reported such as oxazoline-2,4-dione (R. L. Dow et al., J.Med.Chem. 1991,34,1538), 1-oxo-2,4-diazoline-3,5-dione (S. W. Goldstein et al., J.Med.Chem. 1993,36,2238), α-amino carboxylic acid (R. A. DeFronzo, Diabetes, 1988,37,667), and Dicarboxylic acid ester (H. Shinkai et al., J.Med.Chem.1998,41,1927).
- The Subject of Invention
- The present invention concerns ether and amide compounds which enhance insulin action and show hypoglycemic activity with low toxicities and a pharmaceutical composition containing these compounds as active ingredients.
- A Solution to the Problem
- After elaborated to make an anti-diabetic drug, the inventors found that new compounds as show general formula (I) had shown potent anti-diabetic activities and fulfilled this invention.
- Namely, the invention is the compounds as shown in general formula (I) and its pharmaceutically acceptable salts and a composition containing these compounds as active ingredients.
- R1—A—R2 (I)
-
-
-
-
- R8—NHSO2—, R8—NHSO2—CH2—, HOOC—CH2—O—, HSO3N═CH—, or R9—SO2NHCO—;
- R4 is H, OH, O-alkyl or O—CH2OCH3;
- R5 is H, halogen atom, —CH2COOH or OH;
- R6 and R7 are hydrogen, t-butyl or pyrolidyl;
- R8 is hydrogen or lower alkyl;
- R9 is alkyl or thienyl;
- R10 is lower alkyl).
- Enforcement of Invention
-
- Typical preparations of the compounds of general formula (I) according to the invention are shown.
- (I) The preparation of a compound of general formula (I) in which
-
- (wherein: R5, R6, and R7 have the above-mentioned meanings; n=2)
- (a) In case of
-
- in which R3 is CH3SO2NH— or CF3SO2NH— and R4 is H.
- The compounds can be obtained by means of the following reaction diagram: Asparatic acid β-methyl ester (2). (J.Arg.Chem.Soc.Japan, 1951-1952,25,129):C.A.47,6065i or R. L. Prestige et al., J.Org.Chem. 1975,40,3287 as a starting material is converted to compound (3) by the known method (B. Helvin et al., J.Med.Chem. 1992,35,1853) and compound (3) is tosylated or mesylated to obtain compound (4). The coupling reaction of compound (4) with nitrophenol to obtain compound (5) and then compound (5) is reduced with H2—Pd/C to obtain compound (6) and compound (6) is subjected to react with several sulfonyl chloride (7) and sulfonic acid anhydride (8) to obtain the compound of genaral formula (I).
- (b) In case of
-
- in which R3 is HOOCCH2SO2NH— and R4 is H.
- The compounds can be obtained by mean of the following reaction diagram:
- The reaction of compound (6) and EtOOC.CH2SO2Cl as a sulfonyl chloride, namely CH3OOCCH2SO2Cl (9), to obtain the ester (11) and then compound (11) is hydrolyzed to obtain the compound of genaral formula (I).
-
- (c) In case of
-
- in which R3 is HOOC—CONH— and R4 is H.
- The compound can be obtained by means of the following reaction diagram:
-
- in which R3 is CH3SO2NHCH2—, CF3SO2 NHCH2— and HOOC—CONH—, and R4 is H.
- The compound can be obtained by means of the following reaction diagram:
- Compound (4) is reacted with p-hydroxy benzaldehyde to obtain compound (13) and compound (13) is subjected to reductive amination using benzylamine and sodium borohydride to obtain compound (14).
-
- (e) In case of
-
- in which R3 is HOOC— or CH3OOC— and R4 is —OH or —O-alkyl.
- As shown in the following reaction diagram,
-
-
- (f) In case of
-
- in which R3 is NH2SO3— or alkyl-NHSO2— and R4 is —OH.
- As shown in the following reaction diagram,
-
-
- (g) In case of
-
- in which R3 is CH3SO2NH— or CF3SO2NH—.
- As shown in the following reaction diagram,
-
- (h) In case of
-
- in which R3 is —COOH.
- As shown in the following reaction diagram,
-
- (i) In case of
-
- in which R3 is MeOOCCH2—, and R4 is —O-alkyl.
- As shown in the following reaction diagram,
-
- (j) In case of
-
- in which R3 is NH2SO2CH2— or alkyl-NHSO2CH2— and R4 is OH or —O-alkyl.
- As shown in the following reaction diagram,
-
- (II) The preparation of a compound of general formula (I) in which
-
- (wherein: R5, R6, and R7 have the above mentioned meaning; n=3)
- (a) In case of
-
- in which R3 is CH3SO2NH— or CF3SO2NH—, and R4 is H.
- As shown in the following reaction diagram,
- glutamic acid γ-methyl ester (16) is used in stead of aspartic acid β-methyl ester (2). Compound (17) is obtained from compound (16) by the same method as compound (3) is obtained from compound (2).
-
- (III) The preparation of a compound of general formula (I) in which
-
- (a) In case of
-
- in which R3 is CH3SO2NH— or CF3SO2NH—, and R4 is H.
- As shown in the following reaction diagram,
- after the reaction of 2-methyl 5-ethylpyridine (21) and formaldehyde using the reported method (Japanese Patent Publication, 1981-65870), compound (22) is obtained. After compound (22) is halogenated, tosylated or mesylated, obtained compound (23) is coupled with nitrophenol and the resulting compound (24) is hydrogenated to obtain compound (25), by the same method as compound (4) is obtained from compound (3).
-
- (b) In case of
-
- in which R3 is CH3SO2NH— or CF3SO2NH—, and R4 is —OH or —O-alkyl.
- As shown in the following reaction diagram,
-
-
- And compound (42) and (43) can be obtained by using the reported method of coupling reaction of fluorobenzene and alcholol (Bioorg.Med.Chem.Lett., 1994,4 (10),1181). Namely, 2—OMOM (methoxy methyl)-4-fluoro nitrozenzene (45) is reacted with HO—R2 to give compound (46) and resulting compound (46) is reduced to obtain compound (47).
- Compound (47) is reacted with RSO2Cl to obtain compound (48) and after deprotection of MOM-group in compound (48), compound (42) is obtained.
- Instead of compound (45), compound (49) is also converted to compound (41), and compound (43) is obtained from compound (41) by the same method as compound (48) is obtained from compound (46).
-
- (IV) The preparation of a compound of general formula (I) in which
-
- (a) In case of
-
- in which R3 is CH3SO2NH— or CF3SO2NH—, and R4 is —H.
- As shown in the following reaction diagram,
- compound (28), obtained from 2-chloropyridine (26) or 2-methyl amino pyridine (27), is tosylated or mesylated to obtain compound (29). Compound (29) is subjected to coupling reaction with nitro phenol and obtained compound (30) using the same manner to obtain compound (3). Resulting compound (30) is reduced to obtain compound (31) and compound (31) is reacted several sulfonyl chlorides (7), sulfonic acid anhydrides (8), EtOOC.CH2SO2Cl and methyloxalate to obtain the compound of general formula (I).
- (V) The preparation of a compound of general formula (I) in which
- A is —NH—CO—
- (a) In case of
-
- in which R3 is CH3SO2NH— or CF3SO2NH—, and R4 is —H.
- As shown in the following reaction diagram,
-
-
- (b) In case of
-
- in which R3 is R9SO2NHCO— (R9=alkyl or thienyl), and R4 is H.
- As shown in the following reaction diagram,
-
- As pharmaceutical acceptable salts of a compound of general formula (I), sodium salt, potassium salt and inorganic base are mentioned.
- In case of R1 contains pyridine base, salts of inorganic and organic acids are mentioned. As the salt of inorganic acid, hydrochloride and sulfate are mentioned. As the salt of organic acid, acetate, succinate and fumalate are mentioned.
- A compound of general formula (I) can be used itself or formulated to pharmaceutical product such as powder, granule, tablet and capsule by known pharmaceutical technology.
- Hypoglycemic activity in mice
- Test compounds were suspended in 0.5% Methyl cellulose solution and administered (p.o.) to db/db mice (obtained from Nihon Clea) at a range of 3-30 mg/kg once a day for four consecutive days. Troglitazone (300 mg/kg) was also administered for control. The results is shown in Table 1.
- The compound number corresponds to the experimental number.
TABLE 1 Compound No. Dosage (mg/kg) Hypoglycemic activity (%) 1 30 24.6 2 10 49.0 8 10 26.0 9 10 24.0 10 10 32.4 11 10 15.4 18 10 34.7 19 10 12.8 21 10 34.6 24 10 25.7 26 30 15.1 30 30 22.1 31 30 19.0 35 30 28.8 40 30 53.4 42 10 29.6 47 10 25.6 48 30 65.4 50 30 21.9 52 30 10.5 57 3 44.0 58 3 43.4 59 3 18.4 63 3 18.4 67 3 33.1 68 3 21.2 70 30 51.0 Troglitazone 300 34.0 - The following Examples are provided only for the purpose of the preparation of the compound and not restrict the disclosed invention.
- 4-[2-(5-Methyl-2-phenyl-1,3-oxazole-4-yl)ethoxy]benzene methylsulfonamide
- (a) 5-Methyl-4-tosyloxyethyl-2-phenyl-oxazole
- 22.2 g of 5-Methyl-4-hydroxyethyl-2-phenyl-oxazole was dissolved in a mixture of pyridine (13 mL) and dichloroethane (6 mL) and toluenesulfonyl chloride was added slowly to the mixture and stirred at room temperature over night. The reaction mixture was poured into water and extracted with ethyl acetate (50 mL) . The organic extract was washed with satd. CuSO4 solution, H2O and satd. NaCl solution. Removal of solvents after drying over anhydro. Na2SO4, followed by column chromatography (ethyl acetate:n-hexane=1:1) yielded 3.33 g (87.6%) of a white solid of the objective compound.
- MASS(m/e):371(M+),216,186(BP),156,130,105,77,51
- IR(cm−1):1359,1173,966,927,834,813,753,666
-
- (b) 5-Methyl-4-p-nitrophenoxyethyl-2-phenyl-1,3-oxazole
- 0.21 g of NaH was placed in a 50 mL flask and washed twice with n-hexane and added 10 mL of dimethylformamide. 0.67 g of p-nitrophenol was added to the solution at 0° C. and stirred for 30 min. To this mixture, the compound (1.8 g) obtained from the above mentioned step (a) in dimethyl formamide (5 mL) was added and stirred at 80° C. over night. After cooling, the reaction mixture was poured into water and the product was extracted with ethyl acetate (80 mL). The ethyl acetate phase was washed with H2O, satd. NaCl solution and dried over Na2SO4 and filtered. Evaporation of the filtrate gave a residue, from which 1.24 g (75.6%) of the yellowish objective compound was obtained by silicagel column chromatography (ethyl acetate:n-hexane=1:3). m.p.=100-103° C.
- MASS(m/e):338(M+),200,173(BP),130,104,77,51
- IR(cm−1):1590,1500,1332,1263,1107,840
-
- (c) 5-Methyl-4-p-aminophenoxyethyl-2-phenyl-1,3-oxazole
- 1.23 g of the compound obtained from the above mentioned step (b) was dissolved in a solution of 25 mL of methanol-tetrahydrofuran (1:1) and added 0.25 g of 5% Pd—C. To this solution was introduced hydrogen-gas for 1 hour. After filtration of the reaction mixture, the filtrate was evaporated to give a residue, from which 1.02 g (91.1%) of the objective compound was obtained by silicagel column chromatography (ethyl acetate:n-hexane=1:1). m.p.=57-59° C.
- MASS(m/e):308(M+),200(BP),174,104,80,53
- IR(cm−1):1512,1242,825,711,681
-
- (d) 4-[2-(5-Methyl-2-phenyl-1,3-oxazole4-yl)ethoxy]benzene methylsulfonamide (compound 1)
- To a mixture of 0.4 g of the compound obtained from the above mentioned step (c) and 0.28 mL of triethylamine in dichloroethane (4 mL) and 0.16 mL of mesyl chloride were added and stirred at 30° C. for 30 minutes. The reaction mixture was poured into water and extracted with ethyl acetate. The ethyl acetate phase was washed with satd. NH4Cl solution, water and satd. NaCl solution and dried over anhydrous Na2SO4 and filtrated. Evaporation of the filtrate gave a residue, from which 0.34 g (66.7%) of the off-white objective compound was obtained by silicagel column chromatography (ethyl acetate:n-hexane =1:1). m.p.=121-123° C.
- MASS(m/e):372(M+),264,186(BP),149,104,79,55
- IR(cm−1):3238,1506,1320,1281,1245,1212,1143,777
-
- 4-[2-(5-Methyl-2-phenyl-1,3-oxazole4-yl)ethoxy]benzene trifluoromethyl sulfonamide (compound 2)
- To a mixture of the compound (0.4 g) obtained from Example 1 step (c) in 4 mL of dichloromethane and 0.27 mL of triethylamine was added trifluoromethanesulfonic acid anhydride (3.3 mL) and stirred for 30 minutes at 0° C. To the reaction mixture were added 2 mL of methanol and 1 mL of 10% NaOH solution and the mixture was stirred for 10 minutes, followed by addition of water (20 mL) and extracted with ethyl acetate. The extract was washed with satd. NH4Cl, water and satd. NaCl and dried over anhydrous Na2SO4. After filtrating, the extract was evaporated and the residue was purified by silicagel column chromatography. Using a eluants (ethyl acetate:n-hexane=1:1), 0.38 g (66.7%) of the objective compound was obtained. m.p.=97-99° C.
- MASS(m/e):441 (M+),200(BP),173,104,69
- IR(cm−1): 1455,1248,1215,1116,894,597
-
- 5-Methyl-4-[2-(4-carboxymethylsulfonylamino)phenoxy]ethyl-2-phenyl-1,3-oxazole (compound 3)
- (a) 5-Methyl-4-[2-(4-ethoxycarbonylmethyl sulfonylamino)phenoxy]ethyl-2-phenyl-oxazole
- To a solution of the compound (0.36 g) obtained from the above mentioned Example 1 step (c) and triethylamine (0.26 mL) in dichloroethane (8 mL) was slowly added ethoxy carbonyl chloride (0.27 g) at 0° C. and stirred for 2 hours. The reaction mixture was poured into water and the product was extracted with ethyl acetate. The extract was washed with satd. NH4Cl, water and satd. NaCl and dried over anhydrous Na2SO4 and filtrated. Evaporation of the filtrate gave a residue, from which 0.32 g (59.1%) of the oily objective compound was obtained by silicagel column chromatography (ethyl acetate:n-hexane =1:1).
- MASS(m/e):443(M+),186(BP),144,108,84,47
- IR(cm−1): 1734,1341,1299,1248,1158,753
-
- (b) 5-Methyl-4-[2-(4-carboxymethyl sulfonylamino)phenoxy]ethyl-2-phenyl-1,3-oxazole (compound 3)
- To a solution of the compound (0.3 g) obtained from the above mentioned step (a) in ethanol (5 mL) was added 10% NaOH (2.5 mL) and the solution was stirred for 1 hour. After removing the solvent, the residue was dissolved in water and washed with ether. After acidification with 10% HCl, the water phase was extracted with ethyl acetate. The ethyl acetate phase was washed with water, satd. NaCl and dried over anhydrous Na2SO4. After removing the solvent, the residue was recruptallized from ethyl acetate. 0.2 g (71.4%) of the objective compound was obtained. m.p.=164-167° C.
- MASS(m/e):371(M+—COOH),294,186(BP),144,104,77
- IR(cm−1):3274,1713,1512,1338,1281,1245,1158,1107
-
- According to the method described in Example 3, compound 4 (oil), compound 5 (m.p.=273-239° C.), compound 6 (m.p.=143-145° C.) and compound 7 (m.p.=114-116° C.) were obtained.
- 2-[4-(2-(5-Methyl-2-phenyl-1,3-oxazole4-yl)ethoxy)phenyl]amino-2-oxo-acetic acid (compound 8)
- (a) 2-[4-(2-(5-Methyl-2-phenyl-1,3-oxazole-4-yl)ethoxy)phenyl]amino-2-oxo-acetic acid methyl aster
- A mixture of the compound (0.5 g) obtained from the above mentioned Example 1 step (c) and methyl oxalate (0.6 g) in methanol (10 mL) was refluxed over night. After cooling, the solvent was evaporated and a resulting residue was purified by silicagel column chromatography. Chloroform was used as a eluant. 0.55 g (84.6%) of the objective compound was obtained. m.p.=128-132
- MASS(m/e):380(M+),321,186(BP),144,105,59
-
- (b) 2-[4-(2-(5-Methyl-2-phenyl-1,3-oxazole-4-yl)ethoxy)phenyl]amino-2-oxo-acetic acid (compound 8)
- A mixture of the compound (0.53 g) obtained from the above mentioned Example 8 step (a) and 10% NaOH in methanol (15 mL) was stirred for 1 hour and water (30 mL) was added to the mixture, followed by acidification (pH 4) with 10% HCl to give a crptalline product. Recrystallization from ethyl acetate gave the objective compound (0.42 g, 82.3%). m.p.=196-198° C.
- MASS(m/e):366(M+),322,294,186(BP),144,104,77
-
- 2-[4-(2-(5-Methyl-2-phenyl-1,3-oxazole-4-yl)ethoxy)benzyl]trifluoromethylsulfonamide (compound 9)
- (a) 5-Methyl-4-(2-p-benzylaminophenoxy)-ethyl-2-phenyl-1,3-oxazole
- A mixture of 5-methyl-4-[2-(p-formylphenoxy)]ethyl-2-phenyl-1,3-oxazole (0.54 g) and benzylamine (0.21 mL) in methanol (10 mL) was stirred for 10 minutes and NaBH3CN (0.11 g) was added to the mixture. The mixture was stirred over night and evaporated and to a resulting residue was added 10% HCl with stirring, followed by addition of satd. NaHCO3 to alkalize. The product was extracted with ethyl acetate. The ethyl acetate phase was washed with H2O, satd. NaCl and dried over anhydrous Na2SO4 and filtered. Evaporation of the filtrate gave a residue, from which 0.43 (61.4%) of the oily objective product was obtained by silicagel column chromatography.
- MASS(m/e):398(M+),291,212,186(BP),146,104,77
- IR(cm−1):3022,2914,1608,1509,1452,1242,738,714
-
- (b) 5-Methyl-4-(2-p-aminophenoxy)ethyl-2-phenyl-1,3-oxazole
- The compound (0.4 g) obtained from the above mentioned Example 9 step (a) was dissolved in methanol (10 mL) containing a small amount of HOAc and 5% Pd—C (80 mg). The mixture is hydrogenated and the reaction mixture was filtered and the filtrate was evaporated. A resulting residue was purified by silicagel column chromatography using a eluant (CHCl3:MeOH=10:1). The objective compound (0.21 g, 67.7%) was obtained. m.p.=149-152° C.
- MASS(m/e):308(M+),291,186(BP),144,122,104,77
- IR(cm−1):3430,2962,1608,1248
-
- (c) 2-[4-(2-(5-Methyl-2-phenyl-1,3-oxazole4-yl)ethoxy)benzyl]trifluoromethyl sulfonamide (compound 9)
- The compound (0.14 g) obtained from the above mentioned Example 9 step (b) was reacted with trifluoromethanesulfonamide as same manner as Example 2 and the objective compound (compound 9) was obtained (0.55 g, 28%). m.p.=113-115° C.
- MASS(m/e):440(M+),186,144,104(BP),77
- IR(cm−1):3310,1443,1368,1251,1227,1188,1146
-
- 4-[2-(5-Ethylpyridine-2-yl)ethoxy]benzene trifluoromethylsulfonamide (compound 10)
- (a) 2-[2-(4-Nitrophenoxy)]ethyl-5-ethyl-pyridine
- To a mixture of 2-(5-ethylpyridine) ethanol (10 g) and 4-fluoronitrobenzene (9.3 g) in Dimethylformamide (100 mL) was added NaOH (3.4 g) and the mixture was stirred at 0° C. for 1 hour. After pouring into ice-water, the product was extracted with ethyl acetate (150 mL). The ethyl acetate phase was washed with satd. NaCl and dried over anhydrous Na2SO4. After removing the solvent, the resulting residue was purified by silicagel column chromatography (EtoAc:n-hexane=1:2→2:1). Recrystallization from EtoAc n-hexane mixture (1:1) gave the off-white objective compound. 13.4 g (74.4%), m.p.=45-47° C.
- MASS(m/e):272(M+), 150,134(BP), 119,93,77
- IR(cm−1):1593,1518,1491,1341,1260,1008,834
-
- (b) 2-[2-(4-Aminophenoxy)]ethyl-5-ethyl-pyridine
- The compound (1.85 g) obtained from the above mentioned Example 10 step (a) was hydrogenated as same manner as Example 1 step (c) and obtained the oily objective compound (1.62 g, 98.2%).
- MASS(m/e):242(M+), 134(BP), 119,106,83,65
- IR(cm−1):2950,1509,1233,822
-
- (c) 4-[2-(5-Ethylpyridine-2-yl)ethoxy]benzene trifluoromethylsulfonamide (compound 10)
- The compound (1.2 g) obtained from the above mentioned Example 10 step (b) was reacted with trifluoromethanesulfonic acid anhydride by the same procedure described in Example 2 and obtained 0.3 g the objective compound (compound 10). m.p.=76-78° C.
- MASS(m/e):373(M+−1),134(BP),91,69
- IR(cm−1):1446,1263,1119,897,603
-
- 4-[2-(N-Methyl-N-2-pyridyl)aminoethoxy]benzene trifluoromethanesulonamide (compound 11)
- (a) 4-[2-(N-Methyl-N-2-pyridyl)aminoethoxy]-1-nitrobenzene-2-pyridyl-2-methylamino ethanol (4.0 g) was reacted with 4-fluorobenzene by the same procedure described in Example 6 step (a) and obtained the oily objective compound (5.9 g, 82.2%).
- MASS(m/e):273(M+),139,121(BP),94,78,51
- IR(cm−1):2926,1590,1497,1425,1338,1260
-
- (b) 4-[2-(N-Methyl-N-2-pyridyl)aminoethoxy]-1-aminobenzene
- The compound (5.85 g) obtained from the above mentioned Example 11 step (a) was hydrogenated by the same procedure described in Example 1 step (c) and obtained the objective compound (2.12 g, 40.7%).
- MASS(m/e):243(M+), 135(BP),121,108,94,78,65
- IR(cm−1):3334,2914,1596,1557,1503,1425,1233,771
- (c) 4-[2-(N-Methyl-N-2-pyridyl)aminoethoxy]benzene trifluoromethanesulfonamide (compound 11)
- The compound (0.5 g) obtained from the above mentioned Example 11 step (b) was reacted with trifluoromethanesulfonamide by the same procedure described in Example 2 and obtained the objective product (0.67 g, 87.0%). m.p.=60-62° C.
- MASS(m/e):375(M+),304,170,135,108,78(BP),52
- IR(cm−1):1593,1503,1452,1218,1125,891,600
-
- According to the method described in Example 1, compound 12 (m.p.=106-108° C.), compound 13(m.p.=67-68° C.), compound 14 (m.p.=56-58° C.), compound 15 (m.p.=128-130° C.), compound 16 (126-127° C.) and compound 17 (m.p.=128-130° C.) were obtained.
- According to the method described in Example 2, compound 18 (m.p.=197-198° C.), compound 19 (m.p.=70-71° C.) and compound 20 (m.p.=170-172° C.) were obtained.
- 5-Methyl-4-(3-hydroxy)propyl-2-phenyl-1,3-oxazole, prepared from glutamic acid instead of asparatic acid, was reacted as a similar manner described in Experimental 2 and obtained compound 21 (m.p.=113-114° C.).
- According to the same procedure described in Example 4, compound 22 (m.p.=128-130° C.) and compound 23 (m.p.=217° C. (decomp.)) were obtained.
- 2—Hydroxy-4-[2-(5-methyl-2-phenyl-1,3-oxazole4-yl)ethoxy]benzoic acid methyl ester (compound 25)
- 0.2 g of methyl 2-4-dihydroxybenzoate and 0.23 g of diisopropyl azodicarboxylate (DIAD) were dissolved in 2 mL of THF. To this mixture was slowly added a mixture of 0.29 g of 5-methyl-4-hydroxyethyl-3-phenyl-1,3-oxazole and 0.31 g of Ph3P in 3 mL of THF and the mixture was subjected to Mitsunobu reaction. After the reaction mixture was allowed to stand over night, the solvent was removed. The resulting residue was purified by silicagel column chromatography (ethyl acetate:benzene=1:5). After removing the solvent, the residue was recrystallized from benzene. 0.31 g (73.3%) of the colorless objective compound was obtained. m.p.=133-134° C.
- MASS(m/e):353(M+),217,185,136,104(BP),77,53
- IR(cm−1):1677,1617,1440,1320,1251,1188,1134
-
- According to the procedure described in Example 11, compound 26 (m.p.=211-213° C.), compound27 (m.p.=85-87° C.) and compound 28 (m.p.=130-132° C.) were obtained.
- 2—Hydroxy-4-[2-(5-methyl-2-phenyl-1,3-oxazole4-yl)ethoxy]benzoic acid (compound 29)
- 0.17 g of the compound obtained from Example 20 was dissolved in 2 mL of MeOH:THF (1:1). To the solution was added 2 mL of 10% NaOH and the mixture was refluxed for 1 hour. After removal of the solvent, the residue was washed with ether, followed by acidification with 10% HCl. The resulting precipitate was filtered. Recrystallization from ethanol gave the colorless objective compound (0.13 g, 81.3%). m.p.=192-194° C.
- MASS(m/e):339(M+),295,217,186,104(BP)
- IR(cm−1):2920,1655,1260,1170
- According to the above mentioned procedure compound 30 was obtained. (m.p.=246-266° C.).
- 2-Ethoxy-4-[2-(5-methyl-2-phenyl-1,3-oxazole4-yl)ethoxy]benzoic acid (compound 31)
- (a) 2-Ethoxy-4-[2-(5-methyl-2-phenyl-1,3-oxazole4-yl)ethoxy]benzoic acid methyl ester
- To a solution of the compound 25 (0.27 g) in DMF (5 mL) was added K2CO3 (0.16 g) and EtI (0.07 mL) and the mixture was allowed to stand over night. The reaction mixture was poured into water and the product was extracted with ethyl acetate (30 mL). The ethyl acetate phase was washed with water, satd. NaCl and dried over anhydrous Na2SO4 and filtrated. Evaporation of the filtered gave a residue, from which 0.28 g (96.6%) of the colorless objective compound was obtained by silicagel column chromatography (ethyl acetate:n-hexane =1:3).
- MASS(m/e):381(M+),217,186,144,104(BP),77,51
- IR(cm−1):2926,1686,1605,1257,1194
- (b) 2-Ethoxy-4-[2-(5-methyl-2-phenyl-1,3-oxazole-4-yl)ethoxy]benzoic acid (compound 31)
- The compound obtained from above mentioned Example 31-32 step (a) was hydrolyzed by the procedure in Example 29 and obtained the objective compound (0.22 g). m.p.=128-130° C.
- MASS(m/e):367(M+),217,186,144,104(BP),77,51
- IR(cm−1):1686,1605,1572,1281,1263,1239,1191
-
- And compound 25 was reacted with methoxy methylchloride to obtain compound 32. m.p.=129-130° C.
- Each compounds of 3-benzyl-4-nitrophenol-2,6-difluoro-4-nitrophenol and 5-methyl-4-hydroxyethyl-2-phenyl-1,3-oxazole were subjected to Mitsunobu reaction in a similar manner described in Example 25 and the nitro compounds were obtained, followed by the procedures described in Example 1 step (c) and step (d) yielded compound 33 (m.p.=155-156° C.), compound35 (m.p.=143-144° C.) and compound 36 (m.p.=78-80° C.). Further, Mitsunobu reaction of 2,4-dihydroxy-benzene sulfonamide and 5-methyl-4-hydroxy-3-phenyl-1,3-oxazole yielded compound 34 (m.p.=231-232° C.). Ethylation of the compound 34 yielded compound 37 (m.p.=171-173° C.). Methyl 4-hydroxy-2-ethoxyphenoxy acetate was reacted in a similar manner and the resulting compound was hydrolyzed to obtain compound 38 (m.p.=154-156° C.).
- 4-[2-(N-Methyl-N-2-pyridyl)aminoethoxy]-2-hydroxyphenyl trifluoromethane sulfonamide (compound 39)
- (a) 4-[2-(N-Methyl-2—N-pyridyl)aminoethoxy]-2-hydroxy nitrobenzene.
- To a mixture of 2-(N-methyl, N-hydroxyethyl)-aminopyridine (0.35 g) and 4-fluoro-2-methoxy-methyloxy-nitrobenzene in DMF (30 mL) was added NaH (0.12 g) and stirred at room temperature over night. The reaction mixture was poured into ice-water and extracted with ethyl acetate. The ethyl acetate extract was washed with satd. NHCl and dried over anhyd. Na2SO4 and filtered. After removal of solvent, the residue was purified by silicagel column chromatography (ethyl acetate:n-hexane=1:2). The oily objective compound (0.44 g, 57.1 %) was obtained.
- MASS(m/e):333(M+),121(BP),78,52
- IR(cm−1):2926,1596,1500,1425,1341,1287,1152
- (b) 4-[2-(N-Methyl-N-2-pyridyl)aminoethoxy]-2-hydroxyphenyl trifluoromethanesulfonamide (compound 33)
- The compound obtained from the above mentioned step (a) was reduced with hydrogen in a similar manner described in Example 1 step (c) and the resulting compound was reacted with trifluoromethanesulfonic acid anhydride in a similar manner described in Experimental 1 step (d). After removing of the protection group (MOM, methoxymethyl), the residue was recrystallized from the mixture of ethyl acetate and n-hexane to obtain the colorless objective compound (compound 33). mp-134-135° C.
- MASS(m/e):391 (M+),135(BP),107,78
- IR(cm−1):1611,1509,1419,1404,1227,1176,1146
-
- Compound 40 (m.p.=133-135° C.) and compound 41(m.p.=151-153° C.) were obtain from 4-fluoro-2-ethoxy-nitrobenzene by proceeding in a similar manner described in Experimental 39 step (a).
- In stead of 2-(N-Methyl, N-hydroxyethyl) aminopyridine in Example 39 step (a), 5-methyl-4-hydroxy-2-phenyl-1,3-oxazole was reacted in a similar manner and the resulting compound was reacted with trifluoromethanesulfonic acid anhydride to obtain compound 43 (m.p.=169-171° C.). The compound obtained from Example 39 step (a) was reacted with trifluoromethanesulfonic acid anhydride to obtain compound 44 (m.p.=124-125° C.). Further, 2-(N-Methyl, N-hydroxyethyl)-amino pyridine in Example 39 step (a) was reacted with 4-fluoro-2-methoxy-nitrobenzene and the resulting product was treated with in a similar manner described in Example 1 step (c) to obtain the oily objective compound 45.
- N-Butyl-2,4-dihydroxy-benzenesulfonamide and 5-methyl-4-bromoethyl-2-phenyl-1,3-oxazole was reacted in a similar manner described in Example 1 step (b) to obtain compound 46 (m.p.=137-139° C.). After reacting 2,6-dibromo-4-hydroxy-benzoic acid methyl ester and 5-methyl-4-bromoetyl-2-phenyl-1,3-oxazole, compound 47 (m.p.=163-164° C.) was obtained.
- After chlorination of the compound of general formula (68), the resulting compound was reacted with 4-nitroaniline or corresponding aniline to obtain the compound of general formula (69), followed by reduction in a similar manner described in Example 1 and the resulting compounds were treated in a similar manner described in Example 2. The following objective compounds were obtained. Compound 53 was hydrolyzed to obtain compound 54. Compound 48 (m.p.=147-149° C.), compound 49 (m.p.=175-177° C.), compound 50 (m.p=166-168° C.), compound 51 (m.p.=164-166° C.), compound 52 (m.p.=227-229° C.), compound 53 (oil), compound 54 (175° C., decomp.)
- After activation of carboxylic acid group in general formula (71) by the reported method (Bioorg.Med.Chem.Lett., 1995,1155), the resulting compound was reacted with sulfamines in the presence of DBU to obtain compound 55 (m.p.=150-152° C.) and compound 56 (m.p.=214-216° C.).
- In stead of 5-methyl-4-p-aminophenoxy-2-phenyl-1,3-oxazole in Example 2, 5-methyl-4-p-aminophenoxyethyl-2-p-tolyl-1,3-oxazole, 5-methyl-4-p-aminophenoxyethyl-2-p-chlorophenyl-1,3-oxazole and 5-methyl-4-p-aminophenoxyethyl-2-p-fluorophenyl-1,3-oxazole were reacted in a similar manner described in Example 2 to obtain the following compounds. Compound 57 (m.p.=173.5-175° C.), compound 58 (m.p.=189-190° C.), compound 59 (m.p.=161-163° C.).
- In stead of 5-methyl-4-p-aminophenoxy-2-phenyl-1,3-oxazole, 5-isopropyl-4-p-aminophenoxy-ethyl-2-p-tolyl-1,3-oxazole, 5-isopropyl-4-p-aminophenoxy-2-phenyl-1,3-oxazole, 5-isopropyl-4-p-aminophenoxyethyl-2-p-fluorophenyl-1,3-oxazole and 5-isopropyl-4-p-aminophenoxy-2-(3,5-di-t-butyl-4-hydroxy)phenyl-1,3-oxazole were reacted in a similar manner described in Example 2 to obtain the following compounds. Compound 60 (m.p.=190-191° C.), compound 61 (m.p.=155-156° C.), compound 62 (m.p.=189-190° C.), compound 63 (m.p.=142-144° C.). Example 64-66
- 5-Isopropyl-4-hydroxyethyl-2-phenyl-1,3-oxazole, 5-isopropyl-4-hydroxyethyl-2-p-phenyl-1,3-oxazole and 5-isopropyl-4-hydroxyethyl-2-p-tolyl-1,3-oxazole were reacted with 4-fluoro-2-ethoxy-nitrobenzene in a similar manner described in Example 39 to obtain the following compounds. Compound 64 (m.p.=142-144° C.), compound 65 (m.p.=179-181° C.), Compound 66 (m.p.=122-124° C.)
- Each of 5-methyl-4-hydroxyethyl-2-(p-ethoxycarbonylmethyloxy)phenyl-1,3-oxazole and 5-methyl-4-hydroxyethyl-2-(3,5-di-t-butyl-4-ethoxycarbonylmethyloxy)phenyl-1,3 -oxazole were transformed to 5-methyl-4-p-nitrophenyl -2-(p-ethoxycarbonylmethyloxy)phenyl-1,3-oxazole and 5-methyl-4-p-nitrophenyl-2-(3,5-di-t-butyl-4-ethoxycarbomethyloxy)phenyl-1,3-oxazole using a similar method described in Example 39. The resulting compounds were hydrolyzed with 10% NaOH—MeOH to obtain the following compounds. Compound 67 (m.p.=167-168° C.), compound 68 (m.p.=196-198° C.)
- 5-Methyl-4-p-formylphenyl-2-phenyl-1,3-oxazole (1.0 g) was dissolved in dichlolomethane (10 mL) and hydroxylamine-o-sulfonic acid (0.59 g) was added. The mixture was stirred for 30 minutes and the resulting precipitate was collected, followed by washing with water, MeOH and dichloromethane. 1.03 g of compound 69 was obtained. m.p.=165-167° C.
- MASS(m/e):403(M+1),401(M−1)
- According to a similar procedure, described in Example 2, 5-methyl-4-aminophenoxyethyl-2-(3-t-butyl-4-hydroxy)phenyl-1,3-oxazole were transformed to compound 70. m.p.=58-60° C.
- Effects of the Invention
- This invention concerns to novel ether and/or amide derivatives which enhance insulin action and show hypoglycemic activities with low toxicities and useful for antidiabetics.
Claims (19)
1. A compound of the general formula (I),
then n is 1 or 2. R3 is OH—, CH3SO2NH—, CF3SO2NH—, CH3SO2NHCH2—, CF3SO2NHCH2—, HOOC—, CH3OOC—,
R8—NHSO2—, R8—NHSO2—CH2—, HOOC—CH2—O—, HSO3N═CH—, or R9—SO2NHCO—;
R4 is H, OH, O-alkyl or O—CH2OCH3;
R5 is H, halogen atom, —CH2COOH or OH;
R6 and R7 are hydrogen, t-butyl or pyrolidyl;
R8 is hydrogen or lower alkyl;
R9 is alkyl or thienyl;
R10 is lower alkyl)
or a pharmaceutically acceptable salt.
6. A pharmaceutical composition according to for use as antidiabetics.
claim 1
(in which R2 and R4 have the above-mentioned meaning) is reduced to obtain a compound of general formula;
(in which R2 and R4 have the above-mentioned meaning) is reacted with CH3SO2Cl or CF3SO2Cl to obtain the compound of the general formula (I).
(in which R2 has the above-mentioned meaning) is reacted with CH3SO2Cl or CF3SO2Cl to obtain the compound of general formula (I).
9. A process for the production of a compound of the general formula (I) wherein A is —O—; R has the above-mentioned meanings;
is reacted with a compound of general formula;
X—R2
(in which X is Br, tosyl or mesyl; R2 has the above-mentioned meanings) to obtain a compound of general formula;
and followed by hydrolysis to obtain the compound of general formula (I).
10. A process for the production of a compound of the general formula (I) wherein A is —O—; R2 has the above-mentioned meanings;
is reacted with a compound of general formula;
HO—R2
(in which R2 has the above-mentioned meanings) and followed by hydrolysis to obtain the compound of general formula (I).
11. A process for the production of a compound of general formula (I) wherein A is —O—;
(in which R2 has the above-mentioned meaning) after debenzylation, is converted to a compound of general formula;
(in which R2 has the above-mentioned meanings) is reacted with CH3SO2Cl or CF3SO2Cl to obtain the compound of general formula (I).
12. A process for the production of a compound of the general formula (I) wherein A is —O—;
(in which R2 has the above-mentioned meanings) then reacted with EtOOC—CH2—SO2Cl to obtain a compound of general formula;
(in which R2 has the above-mentioned meanings) and followed by hydrolysis to obtain the compound of general formula (I).
13. A process for the production of a compound of the general formula (I) wherein A is —O—;
(in which R2 has the above-mentioned meaning) and then hydrolyzed to obtain the compound of general formula (I).
14. A process for the production of a compound of the general formula (I) wherein A is —O—;
to obtain the compound of genaral formula (I).
15. A method of manufacturing a compound of the general formula (I) wherein A is —O—;
(in which R2 has the above-mentioned meanings) and then reacted with methyloxalate to obtain a compound of general formula;
(in which R2 has the above-mentioned meaning) and subjected to hydrolyzed to obtain the compound of genaral formula (I).
16. A method for manufacturing a compound of the genaral formula (I) wherein A is —O—;
with a compound of general formula;
HO—R2
(in which R2 has the above-mentioned meanings) in the presence of NaH to obtain a compound of general formula (I).
17. A method for manufacturing a compound of the general formula (I) wherein A is —O—;
(in which R2 has the above-mentioned meanings) with thienyl sulfonamide or methyl sulfonamide in the presence of 1,8-Diazabicyclo [5,4,0]undeca-7-en to obtain the compound of general formula (I).
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP6106/2000 | 2000-01-11 | ||
JP2000-006106 | 2000-01-11 | ||
JP2000006106 | 2000-01-11 | ||
JP2000-356303 | 2000-11-22 | ||
JP2000356303A JP4316787B2 (en) | 2000-01-11 | 2000-11-22 | An ether or amide derivative, a process for producing the same, and a therapeutic agent for diabetes containing the same, |
Publications (2)
Publication Number | Publication Date |
---|---|
US20010008898A1 true US20010008898A1 (en) | 2001-07-19 |
US6414001B2 US6414001B2 (en) | 2002-07-02 |
Family
ID=26583525
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/756,701 Expired - Fee Related US6414001B2 (en) | 2000-01-11 | 2001-01-10 | Ether and amide compounds preparation thereof composition containing same and use thereof as antidiadetics |
Country Status (9)
Country | Link |
---|---|
US (1) | US6414001B2 (en) |
JP (1) | JP4316787B2 (en) |
KR (1) | KR20010070442A (en) |
CN (1) | CN1227231C (en) |
DE (1) | DE10100772B4 (en) |
ES (1) | ES2187261B2 (en) |
FR (1) | FR2804681B1 (en) |
GB (1) | GB2359082B (en) |
IT (1) | ITMI20010042A1 (en) |
Cited By (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002088120A1 (en) * | 2001-04-26 | 2002-11-07 | Léciva, a.s. | Method for obtaining pioglitazone as an antidiabetic agent |
US20030171377A1 (en) * | 2001-08-29 | 2003-09-11 | Bigge Christopher Franklin | Antidiabetic agents |
US6716842B2 (en) | 2002-04-05 | 2004-04-06 | Warner-Lambert Company, Llc | Antidiabetic agents |
US20040176395A1 (en) * | 2002-12-31 | 2004-09-09 | Flynn Daniel L | Anti-cancer medicaments |
US20050267665A1 (en) * | 2004-05-12 | 2005-12-01 | Toyota Jidosha Kabushiki Kaisha | Deceleration control system and deceleration control method for vehicle |
US20050288286A1 (en) * | 2003-12-24 | 2005-12-29 | Flynn Daniel L | Anti-inflammatory medicaments |
WO2006018116A1 (en) * | 2004-08-14 | 2006-02-23 | Sanofi-Aventis Deutschland Gmbh | N-(phenyl-oxazol-4-ylmethoxymethyl)-cyclohexyl-succinic acid amide derivatives and related compounds which are used as ppar-ligands (peroxisome proliferator-activated receptors) for the treatment of hyperlipidaemie and diabetes |
US7144911B2 (en) | 2002-12-31 | 2006-12-05 | Deciphera Pharmaceuticals Llc | Anti-inflammatory medicaments |
US20080045706A1 (en) * | 2002-12-31 | 2008-02-21 | Flynn Daniel L | Anti-inflammatory medicaments |
KR100913471B1 (en) | 2001-10-25 | 2009-08-25 | 일라이 릴리 앤드 캄파니 | Thiopene- and Thiazolesulfonamides as Antineoplastic Agents |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EA200300286A1 (en) | 2000-08-23 | 2003-08-28 | Эли Лилли Энд Компани | AGONISTS OF RECEPTORS ACTIVATED BY PEROXISOMAL PROLIFERATOR |
AU2001284658A1 (en) | 2000-08-23 | 2002-03-13 | Eli Lilly And Company | Oxazolyl-aryloxyacetic acid derivatives and their use as ppar agonists |
JP2004506722A (en) | 2000-08-23 | 2004-03-04 | イーライ・リリー・アンド・カンパニー | Methods of modulating peroxisome proliferator-activated receptors |
HUP0400268A2 (en) | 2001-06-07 | 2004-07-28 | Eli Lilly And Co. | Modulators of peroxisome proliferator activated receptors (ppar), their use and pharmaceutical compositions containing them |
CA2512883A1 (en) | 2003-02-14 | 2004-09-02 | Eli Lilly And Company | Sulfonamide derivatives as ppar modulators |
US7348453B2 (en) * | 2003-09-04 | 2008-03-25 | Mirus Bio Corporation | Labile linkage for compound delivery to a cell |
SI1650186T1 (en) * | 2004-10-22 | 2008-12-31 | Bioprojet Soc Civ | Novel dicarboxylic acid derivatives |
CN101735048A (en) * | 2008-11-05 | 2010-06-16 | 上海慈瑞医药科技有限公司 | Salicylic acid compounds with insulin-sensitizing activity and preparation method thereof |
CN104718188B (en) | 2012-05-22 | 2018-08-21 | 基因泰克公司 | The benzamides of N- substitutions and its purposes in treating pain |
CN104797555B (en) | 2012-07-06 | 2017-12-22 | 基因泰克公司 | The benzamide and its application method of N substitutions |
JP2015535252A (en) | 2012-10-26 | 2015-12-10 | メルク・シャープ・アンド・ドーム・コーポレーションMerck Sharp & Dohme Corp. | N-substituted indazolesulfonamide compounds having selective activity in voltage-gated sodium channels |
CN112028833B (en) * | 2020-09-25 | 2022-07-05 | 西南大学 | Para-aminosalicylic acid azole derivative and preparation method and application thereof |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
HU217432B (en) * | 1988-03-08 | 2000-01-28 | Pfizer Inc. | Process for producing thiazolidine-dion derivatives and pharmaceutical compositions containing the same the compounds and compositions |
US5239080A (en) * | 1989-02-08 | 1993-08-24 | Takeda Chemical Industries, Ltd. | Oxazole compounds and their use as antidiabetic and bone-reduction inhibitory agents |
CA2087437A1 (en) * | 1990-08-23 | 1992-02-24 | Steven W. Goldstein | Hypoglycemic hydroxyurea derivatives |
TW245716B (en) * | 1992-12-28 | 1995-04-21 | Takeda Pharm Industry Co | |
TW268952B (en) * | 1993-02-26 | 1996-01-21 | Takeda Pharm Industry Co Ltd | |
US5641796A (en) * | 1994-11-01 | 1997-06-24 | Eli Lilly And Company | Oral hypoglycemic agents |
GB9604242D0 (en) * | 1996-02-28 | 1996-05-01 | Glaxo Wellcome Inc | Chemical compounds |
BR9711627A (en) * | 1996-08-19 | 1999-08-24 | Japan Tobacco Inc | Propionic acid derivatives and their use |
EP1067109B1 (en) * | 1998-03-10 | 2009-12-09 | Ono Pharmaceutical Co., Ltd. | Carboxylic acid derivatives and drugs containing the same as the active ingredient |
EP1214301A1 (en) * | 1999-08-27 | 2002-06-19 | Eli Lilly And Company | Hypoglycemic n,n-arylsulfonylglycine compounds |
US6617342B1 (en) * | 1999-08-27 | 2003-09-09 | Eli Lilly And Company | Hypoglycemic sulfonyl pyrazolones and pyrazolines |
-
2000
- 2000-11-22 JP JP2000356303A patent/JP4316787B2/en not_active Expired - Fee Related
-
2001
- 2001-01-05 KR KR1020010000631A patent/KR20010070442A/en not_active Application Discontinuation
- 2001-01-08 GB GB0100433A patent/GB2359082B/en not_active Expired - Fee Related
- 2001-01-09 FR FR0100207A patent/FR2804681B1/en not_active Expired - Fee Related
- 2001-01-10 DE DE10100772A patent/DE10100772B4/en not_active Expired - Fee Related
- 2001-01-10 US US09/756,701 patent/US6414001B2/en not_active Expired - Fee Related
- 2001-01-10 ES ES200100058A patent/ES2187261B2/en not_active Expired - Fee Related
- 2001-01-11 CN CNB011047011A patent/CN1227231C/en not_active Expired - Fee Related
- 2001-01-11 IT IT2001MI000042A patent/ITMI20010042A1/en unknown
Cited By (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7009057B2 (en) | 2001-04-26 | 2006-03-07 | Zentiva A.S. | Method for obtaining pioglitazone as an antidiabetic agent |
WO2002088120A1 (en) * | 2001-04-26 | 2002-11-07 | Léciva, a.s. | Method for obtaining pioglitazone as an antidiabetic agent |
US20050043360A1 (en) * | 2001-04-26 | 2005-02-24 | Leciva, A.S. | Method for obtaining pioglitazone as an antidiabetic agent |
US20030171377A1 (en) * | 2001-08-29 | 2003-09-11 | Bigge Christopher Franklin | Antidiabetic agents |
KR100913471B1 (en) | 2001-10-25 | 2009-08-25 | 일라이 릴리 앤드 캄파니 | Thiopene- and Thiazolesulfonamides as Antineoplastic Agents |
US6716842B2 (en) | 2002-04-05 | 2004-04-06 | Warner-Lambert Company, Llc | Antidiabetic agents |
US7737283B2 (en) | 2002-12-31 | 2010-06-15 | Deciphera Pharmaceuticals, Llc | Anti-inflammatory medicaments |
US7666895B2 (en) | 2002-12-31 | 2010-02-23 | Deciphera Pharmaceuticals, Llc | Anti-inflammatory medicaments |
US20080132506A1 (en) * | 2002-12-31 | 2008-06-05 | Flynn Daniel L | Anti-inflammatory medicaments |
US20070037808A1 (en) * | 2002-12-31 | 2007-02-15 | Flynn Daniel L | Anti-inflammatory medicaments |
US20040176395A1 (en) * | 2002-12-31 | 2004-09-09 | Flynn Daniel L | Anti-cancer medicaments |
US7144911B2 (en) | 2002-12-31 | 2006-12-05 | Deciphera Pharmaceuticals Llc | Anti-inflammatory medicaments |
US20090105230A1 (en) * | 2002-12-31 | 2009-04-23 | Flynn Daniel L | Anti-inflammatory medicaments |
US7279576B2 (en) | 2002-12-31 | 2007-10-09 | Deciphera Pharmaceuticals, Llc | Anti-cancer medicaments |
US20080045706A1 (en) * | 2002-12-31 | 2008-02-21 | Flynn Daniel L | Anti-inflammatory medicaments |
US20080045531A1 (en) * | 2002-12-31 | 2008-02-21 | Flynn Daniel L | Anti-inflammatory medicaments |
US7342037B2 (en) | 2002-12-31 | 2008-03-11 | Deciphera Pharmaceuticals, Llc | Anti-inflammatory medicaments |
US20080299639A1 (en) * | 2002-12-31 | 2008-12-04 | Flynn Daniel L | Anti-inflammatory medicaments |
US20050288286A1 (en) * | 2003-12-24 | 2005-12-29 | Flynn Daniel L | Anti-inflammatory medicaments |
US7202257B2 (en) | 2003-12-24 | 2007-04-10 | Deciphera Pharmaceuticals, Llc | Anti-inflammatory medicaments |
US20050267665A1 (en) * | 2004-05-12 | 2005-12-01 | Toyota Jidosha Kabushiki Kaisha | Deceleration control system and deceleration control method for vehicle |
US20070197605A1 (en) * | 2004-08-14 | 2007-08-23 | Sanofi-Aventis Deutschland Gmbh | Arylcycloakyl-substituted alkanoic acid derivatives useful as peroxisome proliferator-activated receptor (ppar) ligands for the treatment of hyperlipidemia and diabetes |
US7598281B2 (en) | 2004-08-14 | 2009-10-06 | Sanofi-Aventis Deutschland Gmbh | Arylcycloakyl-substituted alkanoic acid derivatives useful as peroxisome proliferator-activated receptor (PPAR) ligands for the treatment of hyperlipidemia and diabetes |
WO2006018116A1 (en) * | 2004-08-14 | 2006-02-23 | Sanofi-Aventis Deutschland Gmbh | N-(phenyl-oxazol-4-ylmethoxymethyl)-cyclohexyl-succinic acid amide derivatives and related compounds which are used as ppar-ligands (peroxisome proliferator-activated receptors) for the treatment of hyperlipidaemie and diabetes |
Also Published As
Publication number | Publication date |
---|---|
JP4316787B2 (en) | 2009-08-19 |
CN1315320A (en) | 2001-10-03 |
KR20010070442A (en) | 2001-07-25 |
DE10100772A1 (en) | 2001-07-19 |
US6414001B2 (en) | 2002-07-02 |
JP2001261662A (en) | 2001-09-26 |
ES2187261B2 (en) | 2004-07-16 |
ES2187261A1 (en) | 2003-05-16 |
GB2359082B (en) | 2004-09-29 |
ITMI20010042A1 (en) | 2002-07-11 |
DE10100772B4 (en) | 2005-09-22 |
GB2359082A (en) | 2001-08-15 |
FR2804681A1 (en) | 2001-08-10 |
GB0100433D0 (en) | 2001-02-21 |
FR2804681B1 (en) | 2004-06-25 |
CN1227231C (en) | 2005-11-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6414001B2 (en) | Ether and amide compounds preparation thereof composition containing same and use thereof as antidiadetics | |
US20070149589A1 (en) | Process for the Preparation of 4-(benzimidazolylmethylamino)benzamidines | |
SK282080B6 (en) | Substituted salicylic acids | |
US5710152A (en) | Benzoazine derivative or salt thereof and pharmaceutical compostion comprising the same | |
JP2767321B2 (en) | Piperazine derivative and drug containing the same | |
EP0398179B1 (en) | Rhodanine derivatives and pharmaceutical compositions | |
ES2279310T3 (en) | DERIVATIVES OF HETEROCICLIC OXIMES, ITS PREPARATION PROCEDURE AND ITS USE IN THE TREATMENT OF TYPE II DIABETES. | |
JP4571075B2 (en) | Amide type carboxamide derivatives | |
US5063246A (en) | Phenethylamine derivative compositions and use | |
EP0735029B1 (en) | Benzothiazole derivatives | |
JP2006298909A (en) | Medicine composition | |
JPS6321666B2 (en) | ||
US6727266B2 (en) | Substituted tryptophan derivatives | |
US4912135A (en) | Amide compounds | |
HU202506B (en) | Process for producing benzoxazolone derivatives | |
JP3466273B2 (en) | Tetrazole derivative, method for producing the same, and medicament comprising the same | |
JPH03178965A (en) | Pyridonitrile useful in therapy of cardiovascular affection | |
US6919328B1 (en) | Tricyclic compounds with NOS activity | |
JP3529112B2 (en) | 2- [2- (substituted amino) benzylthio] -5,6,7,8-tetrahydropyrido [4,3-d] pyrimidin-4 (3H) -one derivative | |
US5041462A (en) | Novel substituted acetamide compounds and use as anti-allergic agents | |
US6339083B1 (en) | Multiheterocyclic pharmAceuticals | |
JP2000355537A (en) | Sodium ion/calcium ion exchange system inhibitor | |
JPH0576471B2 (en) | ||
JPH0912563A (en) | New benzylalcohol derivative, its production and its use | |
JP2000281656A (en) | Phenylazole compound, its production and antihyperlipemia medicine |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: KOTOBUKI PHARMACEUTICAL CO., LTD., JAPAN Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:TOMIYAMA, TSUYOSHI;TOMIYAMA, AKIRA;TOMIYAMA, HIROSHI;AND OTHERS;REEL/FRAME:011540/0272 Effective date: 20010122 |
|
FPAY | Fee payment |
Year of fee payment: 4 |
|
REMI | Maintenance fee reminder mailed | ||
LAPS | Lapse for failure to pay maintenance fees | ||
STCH | Information on status: patent discontinuation |
Free format text: PATENT EXPIRED DUE TO NONPAYMENT OF MAINTENANCE FEES UNDER 37 CFR 1.362 |
|
FP | Expired due to failure to pay maintenance fee |
Effective date: 20100702 |